Market closed
Nautilus Biotechnolgy/$NAUT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Nautilus Biotechnolgy
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
Ticker
$NAUT
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
161
Website
NAUT Metrics
BasicAdvanced
$221M
Market cap
-
P/E ratio
-$0.56
EPS
1.03
Beta
-
Dividend rate
Price and volume
Market cap
$221M
Beta
1.03
52-week high
$3.45
52-week low
$1.74
Average daily volume
166K
Financial strength
Current ratio
16.648
Quick ratio
16.233
Long term debt to equity
12.356
Total debt to equity
14.128
Management effectiveness
Return on assets (TTM)
-17.62%
Return on equity (TTM)
-28.04%
Valuation
Price to book
0.99
Price to tangible book (TTM)
0.99
Price to free cash flow (TTM)
-3.612
Growth
Earnings per share change (TTM)
16.57%
3-year earnings per share growth (CAGR)
-4.14%
What the Analysts think about NAUT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Nautilus Biotechnolgy stock.
NAUT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
NAUT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
NAUT News
AllArticlesVideos
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research's Distinguished Investigator Award
GlobeNewsWire·2 months ago
Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference
GlobeNewsWire·2 months ago
Nautilus Biotechnology, Inc. (NAUT) Q3 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Nautilus Biotechnolgy stock?
Nautilus Biotechnolgy (NAUT) has a market cap of $221M as of December 21, 2024.
What is the P/E ratio for Nautilus Biotechnolgy stock?
The price to earnings (P/E) ratio for Nautilus Biotechnolgy (NAUT) stock is 0 as of December 21, 2024.
Does Nautilus Biotechnolgy stock pay dividends?
No, Nautilus Biotechnolgy (NAUT) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next Nautilus Biotechnolgy dividend payment date?
Nautilus Biotechnolgy (NAUT) stock does not pay dividends to its shareholders.
What is the beta indicator for Nautilus Biotechnolgy?
Nautilus Biotechnolgy (NAUT) has a beta rating of 1.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.